MOD GRF(1-29) comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-10-27. Numbers and descriptions here follow the published literature rather than marketing material.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual descriptor; not a measure of purity |
| Solubility class | Freely soluble in water | Aqueous dissolution may require gentle mixing |
| Typical storage (powder) | −20 °C or below, desiccated | Protect from light and ambient moisture |
| Typical storage (solution) | 2–8 °C, short term | Freeze aliquots where longer holding is needed |
| Purity assessment | Reversed-phase HPLC, area percent | Values depend on column, gradient, and detection wavelength |
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
=== 2010s and 2020s === Wolverine joined the Avengers and appeared as a regular character throughout the Avengers (2010–2013) and New Avengers (2010–2013) series, both written by Brian Michael Bendis. Jason Aaron wrote a fourth volume of Wolverine that began in August 2010 and lasted 40 issues. Aaron also wrote a new X-Men storyline, X-Men: Schism (2011), in which Wolverine and Cyclops come into conflict, dividing the team. The same year, he began writing Wolverine and the X-Men, in which Wolverine becomes the headmaster of the Jean Grey School for Higher Learning and must mentor a younger generation of mutants as well as leading one of the X-Men teams. In the Avengers vs. X-Men storyline of 2012, Wolverine sides with the Avengers against his previous team. In 2013, a fifth volume of Wolverine began, written by Paul Cornell and Alan Davis and lasted 13 issues. Cornell then collaborated with Ryan Stegman on Wolverine volume 6 (February 2014 - February 2015). In 2014, Charles Soule wrote the "Death of Wolverine" storyline, in which Wolverine contracts a virus that disables his healing factor, allowing his enemies to finally kill him. He is resurrected in 2018, in the Return of Wolverine miniseries. 2019 saw the beginning of a new era for the X-Men, spearheaded by Jonathan Hickman, starting with the House of X and Powers of X series. This launched the "Krakoan Age", with mutants founding a new nation on the living island of Krakoa, where they are capable of regularly resurrecting mutants after their death.
== External links == "Benzydamine oral rinse". Medicinenet. "Difflam spray (benzydamine)". Net Doctor, UK. 8 March 2020. Archived from the original on 22 December 2006. Retrieved 30 December 2006. "Tantum Verde (benzydamine)". Carysfort Healthcare Limited, Ireland. Archived from the original on 2015-11-25.
=== Toxicity === Acetonitrile has only modest toxicity in small doses. It can be metabolised to produce hydrogen cyanide, which is the source of the observed toxic effects. Generally the onset of toxic effects is delayed, due to the time required for the body to metabolize acetonitrile to cyanide (generally about 2–12 hours). Cases of acetonitrile poisoning in humans are rare but not unknown by inhalation and ingestion. The symptoms, which do not usually appear for several hours after the exposure, include breathing difficulties, slow pulse rate, nausea, and vomiting. Convulsions and coma can occur in serious cases, followed by death from respiratory failure. The treatment is as for cyanide poisoning, with oxygen, sodium nitrite, and sodium thiosulfate among the most commonly used emergency treatments. It has been used in a formulation for removal of sculptured fingernails. At least two cases have been reported of accidental poisoning of young children by acetonitrile-based sculptured nail remover, one of which was fatal. Acetone and ethyl acetate are often preferred as safer for domestic use, and acetonitrile has been banned in cosmetic products in the European Economic Area since March 2000.
These estimates are measured by examining how a ligand binds to a receptor while simultaneously reacting to a substitute agent (antagonist) that will prevent specific binding to occur. Specific binding types to ligand and receptor interactions:
=== Comprehensively sanctioned jurisdictions === Comprehensively sanctioned jurisdictions are subject to the most restrictive sanctions measures. Most transactions between a U.S. person and any person or entity "ordinarily resident" in a comprehensively sanctioned jurisdiction are restricted. In addition to the general sanctions listed below, transactions involving entities or individuals from these countries on OFAC's SDN List or BIS' Entity List are also restricted.
Sources: en.wikipedia.org
=== Passive products === Generally, these products are indicated for only superficial, clean, and dry wounds with minimal exudates. They can also be used as secondary dressings (additional dressings to secure the primary dressing in place or to absorb additional discharge from the wound). Examples are: Gauze, lint, adhesive bandage (plasters), and cotton wool. The main aim is to protect the wound from bacterial contamination. They are also used for secondary dressing. Gauze dressing is made up of woven or non-woven fibres of cotton, rayon, and polyester. Gauze dressing are capable of absorbing discharge from wound but requires frequent changing. Excessive wound discharge would cause the gauze to adhere to the wound, thus causes pain when trying to remove the gauze from the wound. Bandages are made up of cotton wool, cellulose, or polyamide materials. Cotton bandages can act as a secondary dressing while compression bandages provides good compressions for venous ulcers. On the other hand, tulle gras dressing which is impregnated with paraffin oil is indicated for superficial clean wound.
=== Fatality === A systematic meta analysis showed that cannabis users double the chance of dying from heart disease. Cannabis users had a 29% higher risk of heart attack and a 20% higher risk of stroke than non-users. There is an association between cannabis use and suicide, particularly in younger users. A 16-month survey of Oregon and Alaska emergency departments found a report of the death of an adult who had been admitted for acute cannabis toxicity. A recent study in 2025 suggests that individuals diagnosed with cannabis use disorder—characterized by an inability to stop using cannabis despite its negative effects—face a nearly threefold increase in mortality rates compared to those without the condition over a five-year period. The research indicates that people with this disorder are ten times more likely to die by suicide than the general population. Additionally, they have a higher risk of death from trauma, drug poisoning, and lung cancer. In a separate study researchers found an increase in schizophrenia and psychosis cases in Canada linked to cannabis use disorder following the drug's legalization.
== Key factors == There are many factors that contribute to a person's weight, including: diet, physical activity, genetics, environmental factors, health care support, medications, and illnesses. Each of these factors affects weight in different ways and to varying degrees, but health professionals most often stress the importance of diet and physical activity because they can be affected by conscious behavior modification. Attaining a healthy weight involves recognition of general techniques such as portion sizing, self-monitoring, and daily diet consistency. Once this healthy weight has been attained, maintaining this stable weight additionally involves physical activity and control of an individual's environment and eating patterns. Furthermore, healthcare support in the form of primary care medical supervision and following up over time has been shown to be helpful for long-term weight management. The following is a review of some of the key components of weight management in humans.
== Description == It is a large, heavy-bodied snake with a short, broad and flat head with an indistinct canthus and distinct from the neck. It has medium-sized dark eyes with round pupils. The body is cylindrical; the tail is long. The scales are smooth and glossy, in 21–23 rows at midbody. Adults grow to an average of 1.4 to 2.2 metres (4.6 to 7.2 ft) in length, but they can grow to a maximum of 2.8 metres (9.2 ft). Scales are smooth, indicating the largely aquatic life of this species. It is capable of spreading a narrow, yet impressive hood. Body colors are mostly glossy brown, grayish-brown, or reddish-brown with black bands all along the body. The belly is pale yellow, while the tail is wholly black.
Japanese scientists from the Japan Aerospace Exploration Agency (JAXA) have discovered a huge cave on the moon with their Kaguya lunar probe, which could offer astronauts protection from dangerous radiation during future lunar landings, especially during the planned stopover of a Mars mission. As part of a human mission to Mars, astronauts must be protected from cosmic radiation. During Curiosity's mission to Mars, a Radiation Assessment Detector (RAD) was used to measure radiation exposure. The radiation exposure of 1.8 millisieverts per day was mainly due to the constant presence of high-energy galactic particle radiation. In contrast, radiation from the sun accounted for only about three to five percent of the radiation levels measured during Curiosity's flight to Mars. On the way to Mars, the RAD instrument detected a total of five major radiation events caused by solar flares. To protect the astronauts, a plasma bubble will surround the spacecraft as an energy shield and its magnetic field will protect the crew from cosmic radiation. This would eliminate the need for conventional radiation shields, which are several centimeters thick and correspondingly heavy. In the Space Radiation Superconducting Shield (SR2S) project, which was completed in December 2015, magnesium diboride was found to be a suitable material for generating a suitable force field.
Sources: en.wikipedia.org
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.
There is no single agreed limit, and laboratory practice varies widely. Refrigeration slows degradation, and freezing aliquots is often described for longer holding. Any visible cloudiness or precipitate indicates the solution should be discarded.
Mass spectrometry provides the most direct confirmation through molecular mass. Reversed-phase chromatography supports purity assessment, and peptide mapping or amino acid analysis can corroborate sequence. No single method establishes both purity and identity on its own.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.